General Clinical Chemistry Analyzers and Accessories
Abcam LY2940680 (Taladegib), 10MG
MW 512.5 Da. Potent Hedgehog signaling pathway inhibitor. Smoothened antagonist. Inhibits growth of cancer cell lines containing a disease-relevant Smoothened gene mutation. Has anti-tumor activity in animal models.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ledipasvir, 5A of hepatitis C virus inhibitor, 500UG
MW 889 Da. Ledipasvir is an inhibitor of non-structural protein 5A of hepatitis C virus. It has potent effects against genotypes 1a, 1b, 4a, and 5a in vitro, but has lower activity against genotypes 2a and 3a. Ledipasvir can have additive to synergistic in vitro antiviral activity when combined with other agents.
The product is subject to the following: Abcam Restricted Use Statement
Abcam BAY-299, TAF1 and BRD1 inhibitor, 10MG
MW 429.5 Da, Purity >98%. Potent and selective bromodomain inhibitor of TAF1 (IC₅₀ = 8-13 nM) and BRD1 (IC₅₀ = 6-67 nM). More than 30-fold selective versus BRD9 and ATAD2. More than 300-fold selective versus BRD4. Inhibits BRD1 (IC₅₀ = 0.58 μM) and TAF1 (IC₅₀ = 0.9 μM) binding to Histone H4 in cell-based assays; also inhibits BRD1 (IC₅₀ = 0.83 μM) and TAF1 (IC₅₀ = 1.4 μM) binding to Histone H3.3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Sitravatinib, 5MG
MW 629.7 Da, Purity =98%. Broad spectrum receptor tyrosine kinase inhibitor (e.g. Axl, c-Met, PDGFR, VEGFR, Ephrin receptor family, and FLT3). Better efficacy in mouse models than imatinib and crizotinib.
The product is subject to the following: Abcam Restricted Use Statement
Abcam ABT-199 (Venetocla x ), Bcl-2 inhibitor., 1MG
MW 868.4 Da, Purity >98%. Potent, selective Bcl-2 inhibitor (Ki <0.01 nM) that inhibits the growth of Bcl-2–dependent tumors while sparing platelets. Bcl-2–specific BH3 mimetic. Promising agent in the treatment of chronic lymphocytic leukaemic and estrogen receptor-positive breast cancer.
The product is subject to the following: Abcam Restricted Use Statement
Abcam RITA, p53 activator, 5MG
MW 292.4 Da, Purity >98%. p53 activator. Tricyclic thiophene derivative that binds to p53 and induces its accumulation in tumor cells. Prevents p53-HDM2 (MDM2) interaction in vitro and in vivo and affects p53 interaction with several negative regulators. Induces expression of p53 target genes and apoptosis in various tumor cell lines expressing wild-type p53.
The product is subject to the following: Abcam Restricted Use Statement
Abcam TC 14012, Peptidomimetic C x CR4 antagonist, 1MG
MW 2066.4 Da, Purity >95%. TC 14012, Peptidomimetic CXCR4 antagonist. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
AdipoGen 3-Acetyl-6-bromocoumarin
Chemical. CAS 2199-93-1. Formula C11H7BrO3. Molecular Weight 267.1. An intermediate for organic synthesis. Shown to display semiconductor behaviour.
AdipoGen Monosultap
Chemical. CAS 29547-00-0. Formula C5H12NNaO6S4. MW 333.4. Synthetic. Nereistoxin analog insecticide. Insect nicotinic acetylcholine receptors nAChRs channel blocker. Compound can be used as analytical reference material.
Abcam BAY-299, TAF1 and BRD1 inhibitor, 1MG
MW 429.5 Da, Purity >98%. Potent and selective bromodomain inhibitor of TAF1 (IC₅₀ = 8-13 nM) and BRD1 (IC₅₀ = 6-67 nM). More than 30-fold selective versus BRD9 and ATAD2. More than 300-fold selective versus BRD4. Inhibits BRD1 (IC₅₀ = 0.58 μM) and TAF1 (IC₅₀ = 0.9 μM) binding to Histone H4 in cell-based assays; also inhibits BRD1 (IC₅₀ = 0.83 μM) and TAF1 (IC₅₀ = 1.4 μM) binding to Histone H3.3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SGI1776, 10MG
MW 405.4 Da, Purity >99%. Novel ATP competitive inhibitor of Pim1 with IC50 of 7 nM, 50- and 10-fold selective versus Pim2 and Pim3. Preliminary results from studies treating prostate cancer cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ledipasvir, 5A of hepatitis C virus inhibitor, 5MG
MW 889 Da. Ledipasvir is an inhibitor of non-structural protein 5A of hepatitis C virus. It has potent effects against genotypes 1a, 1b, 4a, and 5a in vitro, but has lower activity against genotypes 2a and 3a. Ledipasvir can have additive to synergistic in vitro antiviral activity when combined with other agents.
The product is subject to the following: Abcam Restricted Use Statement
Abcam CUR 61414, Hedgehog signaling pathway antagonist, 25MG
MW 550.7 Da, Purity >98%. Novel, cell permeable Hedgehog signaling pathway antagonist (IC₅₀ = 100-200 nM). Selectively binds to smoothened (Smo) (Ki = 44 nM). Blocks the formation of and induces the regression of basaloid lesions in skin punches and shrinks UV-induced basaloid lesions in adult mouse skin. Inhibits proliferation and induces apoptosis in tumor cells without affecting non-tumor cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LRRK2-IN-1, LRRK2 inhibitor, 50MG
MW 570.7 Da. Potent and selective inhibitor of the Parkinson's disease kinase LRRK2. Benzodiazepine based derivative. Inhibits both G2019S mutant and wild-type LRRK2 kinase activity (IC₅₀ values are 6 and 13 nM respectively). Causes dephosphorylation, ubiquitination and degradation of LRRK2. Inhibits IFN-γ-induced monocyte maturation in vitro.
The product is subject to the following: Abcam Restricted Use Statement
